HIV/AIDS News and Research

RSS

Acquired immune deficiency syndrome or acquired immunodeficiency syndrome (AIDS) is a disease of the human immune system caused by the human immunodeficiency virus (HIV).

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

Immune Network, a company in the business of development and commercialization of immune therapies, announced today that its newly acquired business, Immunitor, has published interim data from the ongoing Phase IIb imm01 clinical trial of V5 in tuberculosis conducted at its second site in Ukraine.

24 Jan 2011

Global Poverty Summit addresses MDGs, global trade policy

At the Global Poverty Summit January 16-19 in Johannesburg, South Africa, "academics, policy-makers, civil society activists and development workers ... agreed that the [U.N. Millennium Development Goals] MDGs have made a difference, but have fallen far short of the ambitious targets on poverty, education, health, gender equality and global partnership that 189 countries committed to achieving by 2015," IRIN reports.

24 Jan 2011

Research findings reveal HIV's hiding spot, new way to stop the virus

HIV adapts in a surprising way to survive and thrive in its hiding spot within the human immune system, scientists have learned. While the finding helps explain why HIV remains such a formidable foe after three decades of research - more than 30 million people worldwide are infected with HIV - it also offers scientists a new, unexpected way to try to stop the virus.

24 Jan 2011

CRI, Oncovir sign new investment agreement to produce immunological stimulant

Cancer Research Institute, a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund, a joint initiative with the Ludwig Institute for Cancer Research, has completed a new investment agreement with Oncovir, a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol- (Poly-ICLC).

24 Jan 2011

CVAF completes new investment agreement with Oncovir for production of Hiltonol

Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund (CVAF), a joint initiative with the Ludwig Institute for Cancer Research (LICR), has completed a new investment agreement with Oncovir, Inc., a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol® (Poly-ICLC).

21 Jan 2011

Roundup: NY Times on mental health cuts; Wis. GOP agenda moves ahead; Minn. Medicaid expansion

Gov. Mark Dayton said during his campaign that enrolling 95,000 people in an expanded Medicaid program would be his top priority when he took office -- and he meant it. Less than three weeks after he was told by members of former Gov. Tim Pawlenty's administration that it could take until October to enact the change, Dayton announced Thursday that it would be done by March 1.

21 Jan 2011

AHF proposes funding solutions to current ADAP crisis

In anticipation of an additional round of cuts to the AIDS Drug Assistance Program (ADAP) to be implemented in the next few months, AIDS Healthcare Foundation (AHF) today proposed three possible funding solutions to the current ADAP crisis—which has left more than 5,000 people on waiting lists to receive lifesaving medications and thousands more scheduled to be disenrolled from the program altogether. Currently,

21 Jan 2011

WHO executive board meeting addresses agency's policy on counterfeit, substandard medications

According to the news service, WHO "members … raised strong concerns that a working group they mandated last May to address problems with WHO policy on counterfeit and substandard medicines has yet to be formed - with four months remaining before it must report back to members."

21 Jan 2011

Scientists find ADAR1 enzyme protect against measles virus

Scientists at The Scripps Research Institute have found that a known enzyme in cells protects against measles virus, likely by altering the virus's genetic material, RNA. Cells lacking the enzyme become highly vulnerable to the virus's destructive effects. The enzyme also protects against several other respiratory viruses, including influenza A.

21 Jan 2011

Elizabeth Glaser foundation awarded $45M grant to address pediatric HIV/AIDS in Zimbabwe

The Government of Zimbabwe's national program to eliminate pediatric HIV/AIDS has received a significant boost with an award by the London-based Children's Investment Fund Foundation (CIFF) to the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF).

20 Jan 2011

FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.

20 Jan 2011

HIV-infected patients three times more likely to suffer strokes

While the overall hospitalization rate for stroke has declined in recent years, the numbers have jumped dramatically for patients infected with human immunodeficiency virus (HIV), suggesting they may be up to three times more likely to suffer a stroke than people uninfected by the virus that causes AIDS.

20 Jan 2011

BI refuses to offer increased access to AIDS drugs for low-income Americans

AHF issued the following: Despite a growing national AIDS drug crisis, pharmaceutical giant Boehringer Ingelheim Pharmaceuticals, has steadfastly refused to offer increased access to its lifesaving AIDS drugs or to respond in any way to repeated requests by AIDS Healthcare Foundation, the largest global AIDS organization, to do its part in creating a solution.

20 Jan 2011

Koronis' KP-1461 drug causes extra mutations to occur in HIV genome in HIV-infected patients

Recently published Phase 2a clinical trial results show that the frequency of specific, drug-induced mutations in the HIV genome can be significantly increased by administering KP-1461, a drug being developed by Koronis Pharmaceuticals based on its novel Viral Decay Acceleration (VDA) drug mechanism.

20 Jan 2011

Swiss HIV Cohort Study identifies simple method to determine time of infection

Identifying the time of HIV infection. Researchers of the Swiss HIV Cohort Study have identified a simple method to establish when a patient contracted the virus causing . The time of infection can be of importance for the treatment of the illness and it contributes to the understanding of the course of the epidemic.

20 Jan 2011

UMB enters license agreement with Bali BioSciences for new strategy to combat sepsis, HIV/AIDS

The University of Maryland, Baltimore's (UMB) Office of Technology Transfer has completed a license agreement with Bali BioSciences LLC, an early-stage company pursuing an unusual, yet clever, strategy to combat disease.

20 Jan 2011

New research: HIV individuals are more likely to have stroke

New research suggests that people infected with human immunodeficiency virus may be up to three times more likely to have a stroke compared to those not affected with HIV. The study is published in the January 19, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

20 Jan 2011

Small molecules may inhibit entry of Ebola into human cells

Ebola, a virus that causes deadly hemorrhagic fever in humans, has no known cure or vaccine. But a new study by University of Illinois at Chicago scientists has uncovered a family of small molecules which appear to bind to the virus's outer protein coat and may inhibit its entry into human cells.

20 Jan 2011

Study: HIV-positive head and neck cancer patients respond well to radiation therapy treatments

HIV-positive head and neck cancer patients respond well to radiation therapy treatments and experience similar toxicity rates as non-HIV-positive patients, despite prior reports to the contrary, according to a study in the January issue of the International Journal of Radiation Oncology•Biology•Physics, an official journal of the American Society for Radiation Oncology.

19 Jan 2011

Scientists determine protein structure that delivers genetic material of HIV to human cells

A team of scientists at The Scripps Research Institute and the University of Virginia has determined the structure of the protein package that delivers the genetic material of the human immunodeficiency virus to human cells.

19 Jan 2011

HIV/AIDS News and Research

Further Reading

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

Global Poverty Summit addresses MDGs, global trade policy

Research findings reveal HIV's hiding spot, new way to stop the virus

CRI, Oncovir sign new investment agreement to produce immunological stimulant

CVAF completes new investment agreement with Oncovir for production of Hiltonol

Roundup: NY Times on mental health cuts; Wis. GOP agenda moves ahead; Minn. Medicaid expansion

AHF proposes funding solutions to current ADAP crisis

WHO executive board meeting addresses agency's policy on counterfeit, substandard medications

Scientists find ADAR1 enzyme protect against measles virus

Elizabeth Glaser foundation awarded $45M grant to address pediatric HIV/AIDS in Zimbabwe

FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA

HIV-infected patients three times more likely to suffer strokes

BI refuses to offer increased access to AIDS drugs for low-income Americans

Koronis' KP-1461 drug causes extra mutations to occur in HIV genome in HIV-infected patients

Swiss HIV Cohort Study identifies simple method to determine time of infection

UMB enters license agreement with Bali BioSciences for new strategy to combat sepsis, HIV/AIDS

New research: HIV individuals are more likely to have stroke

Small molecules may inhibit entry of Ebola into human cells

Study: HIV-positive head and neck cancer patients respond well to radiation therapy treatments

Scientists determine protein structure that delivers genetic material of HIV to human cells

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News